Compare IMMR & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMMR | AGEN |
|---|---|---|
| Founded | 1993 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 229.4M | 126.2M |
| IPO Year | 1999 | 2000 |
| Metric | IMMR | AGEN |
|---|---|---|
| Price | $6.80 | $3.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $12.25 | ★ $14.50 |
| AVG Volume (30 Days) | 562.7K | ★ 636.2K |
| Earning Date | 12-19-2025 | 11-10-2025 |
| Dividend Yield | ★ 4.41% | N/A |
| EPS Growth | ★ 57.07 | N/A |
| EPS | ★ 2.04 | N/A |
| Revenue | ★ $163,133,000.00 | $106,829,000.00 |
| Revenue This Year | $988.71 | $67.15 |
| Revenue Next Year | $109.72 | N/A |
| P/E Ratio | $3.33 | ★ N/A |
| Revenue Growth | ★ 338.21 | N/A |
| 52 Week Low | $5.65 | $1.38 |
| 52 Week High | $9.07 | $7.34 |
| Indicator | IMMR | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 52.53 | 26.40 |
| Support Level | $6.36 | $3.01 |
| Resistance Level | $6.95 | $4.00 |
| Average True Range (ATR) | 0.20 | 0.25 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 60.27 | 11.26 |
Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).